GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amylyx Pharmaceuticals Inc (NAS:AMLX) » Definitions » ROA %

Amylyx Pharmaceuticals (Amylyx Pharmaceuticals) ROA % : 3.85% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Amylyx Pharmaceuticals ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Amylyx Pharmaceuticals's annualized Net Income for the quarter that ended in Dec. 2023 was $18.9 Mil. Amylyx Pharmaceuticals's average Total Assets over the quarter that ended in Dec. 2023 was $492.0 Mil. Therefore, Amylyx Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 was 3.85%.

The historical rank and industry rank for Amylyx Pharmaceuticals's ROA % or its related term are showing as below:

AMLX' s ROA % Range Over the Past 10 Years
Min: -488.11   Med: -146.9   Max: 11.01
Current: 11.01

During the past 5 years, Amylyx Pharmaceuticals's highest ROA % was 11.01%. The lowest was -488.11%. And the median was -146.90%.

AMLX's ROA % is ranked better than
94.99% of 1556 companies
in the Biotechnology industry
Industry Median: -35.515 vs AMLX: 11.01

Amylyx Pharmaceuticals ROA % Historical Data

The historical data trend for Amylyx Pharmaceuticals's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amylyx Pharmaceuticals ROA % Chart

Amylyx Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
-425.96 -488.11 -146.90 -79.82 10.84

Amylyx Pharmaceuticals Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -59.63 1.57 20.50 18.16 3.85

Competitive Comparison of Amylyx Pharmaceuticals's ROA %

For the Biotechnology subindustry, Amylyx Pharmaceuticals's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amylyx Pharmaceuticals's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amylyx Pharmaceuticals's ROA % distribution charts can be found below:

* The bar in red indicates where Amylyx Pharmaceuticals's ROA % falls into.



Amylyx Pharmaceuticals ROA % Calculation

Amylyx Pharmaceuticals's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=49.271/( (391.453+517.454)/ 2 )
=49.271/454.4535
=10.84 %

Amylyx Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=18.924/( (466.584+517.454)/ 2 )
=18.924/492.019
=3.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Amylyx Pharmaceuticals  (NAS:AMLX) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=18.924/492.019
=(Net Income / Revenue)*(Revenue / Total Assets)
=(18.924 / 433.796)*(433.796 / 492.019)
=Net Margin %*Asset Turnover
=4.36 %*0.8817
=3.85 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Amylyx Pharmaceuticals ROA % Related Terms

Thank you for viewing the detailed overview of Amylyx Pharmaceuticals's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Amylyx Pharmaceuticals (Amylyx Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
43 Thorndike Street, Cambridge, MA, USA, 02141
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.
Executives
Joshua B Cohen director, officer: Co-Chief Executive Officer C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Justin B. Klee director, officer: Co-Chief Executive Officer C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Patrick D Yeramian officer: Chief Medical Officer 1815 PARKSIDE CIRCLE SOUTH, BOCA RATON FL 33486
James M Frates officer: Chief Financial Officer 88 SIDNEY ST, CAMBRIDGE MA 021394136
Karen Firestone director C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE ST., CAMBRIDGE MA 02141
Gina Mazzariello officer: Chief Legal Officer C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Morningside Venture Investments Ltd 10 percent owner MCCARTHY LEGAL SERVICES, 1188 CENTRE STREET, NEWTON CENTRE MA 02459
Milne George M Jr director
Margaret Olinger officer: Chief Commercial Officer C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Dragsa 96 Llc 10 percent owner 55 RAILROAD AVE., GREENWICH CT 06830
Als Invest 1 B.v. 10 percent owner EERSTE WELERINGDWARSSTRAAL 54E, 1017 TP, AMSTERDAM P7 1017
Isaac Cheng director C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Mvil, Llc 10 percent owner 22ND FLOOR HANG LUNG CENTRE, 2-20 PATERSON STREET, CAUSEWAY BAY K3 00000
Ole Andreas Halvorsen 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901

Amylyx Pharmaceuticals (Amylyx Pharmaceuticals) Headlines